JNJ Stock Halted by Valuation Concerns

Johnson & Johnson (JNJ) has delivered a strong performance so far this year, outpacing both the S&P 500 ETF and the XLV index with a 28% total return YTD. However, despite solid Q2 results and raised FY 2026 guidance, JNJ's stock is now considered fully priced, warranting a hold rating from analysts.

The company faces key risks including softness in MedTech growth, ongoing litigation, and macro uncertainties, while Pharma momentum drives guidance upgrades. Technically, JNJ remains in an uptrend, but negative RSI divergence and valuation suggest potential near-term consolidation.